Dynavax Technologies (DVAX) Stock Price, News & Analysis

Company Overview

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases. The company’s approach centers on pairing antigen constructs with adjuvant technologies designed to improve efficacy, durability and overall immunogenicity. In parallel, Dynavax is exploring immuno-oncology applications by investigating how its TLR agonists can synergize with checkpoint inhibitors and other cancer therapies.

Dynavax maintains a presence in North America and Europe, both through direct commercialization efforts and strategic partnerships. In addition to its Emeryville headquarters, the company operates research and development facilities in the United Kingdom and collaborates with global pharmaceutical firms to broaden the reach of its vaccine and adjuvant technologies. These alliances have enabled Dynavax to navigate regulatory requirements and facilitate supply chain distribution in multiple regions.

Under the leadership of President and Chief Executive Officer Tony Wood, who joined the company in 2017, Dynavax continues to advance its development programs and expand commercial opportunities. The company’s scientific team includes experts in immunology, infectious disease and vaccine manufacturing, supporting a disciplined approach to clinical research and regulatory strategy. As Dynavax progresses its pipeline through clinical milestones, it aims to address unmet medical needs in both prophylactic and therapeutic settings.

Key Stats

• Today's Range: $15.50 to $15.50
• 50-Day Range: $15.38 to $15.72
• 52-Week Range: $9.20 to $15.73
• Volume: N/A
• Average Volume: 2.20 million shs
• Market Capitalization: $1.82 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

Dynavax Technologies Stock Analysis - MarketRank™

Dynavax Technologies scored higher than 11% of companies evaluated by MarketBeat, and ranked 857th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.8 / 5
• Analyst Rating: Reduce

Consensus Rating

Dynavax Technologies has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Dynavax Technologies has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 53.13%

Earnings Growth

Earnings for Dynavax Technologies are expected to grow by 53.13% in the coming year, from $0.32 to $0.49 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Dynavax Technologies is -41.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dynavax Technologies is -41.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Dynavax Technologies has a P/B Ratio of 3.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for DVAX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dynavax Technologies does not currently pay a dividend.

Dividend Growth

Dynavax Technologies does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for DVAX on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Dynavax Technologies to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Dynavax Technologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.98% of the stock of Dynavax Technologies is held by insiders.

Percentage Held by Institutions

96.96% of the stock of Dynavax Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/05/2025
• Today: 10/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:DVAX
• CIK: 1029142
• Web: www.dynavax.com
• Phone: (510) 848-5100
• Fax: 510-848-1327
• Employees: 350
• Year Founded: 1996

Profitability

• EPS (Trailing Twelve Months): ($0.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 48.44
• P/E Growth: N/A
• Net Income: $27.31 million
• Net Margins: -13.13%
• Pretax Margin: -12.29%
• Return on Equity: 7.18%
• Return on Assets: 4.08%

Debt

• Debt-to-Equity Ratio: 0.41
• Current Ratio: 7.62
• Quick Ratio: 6.94

Sales & Book Value

• Annual Sales: $330.51 million
• Price / Sales: 5.51
• Cash Flow: $0.16 per share
• Price / Cash Flow: 97.88
• Book Value: $4.54 per share
• Price / Book: 3.41

Miscellaneous

• Outstanding Shares: 117,425,000
• Free Float: 113,926,000
• Market Cap: $1.82 billion
• Optionable: Optionable
• Beta: 0.97